Publications - Dr. Andrea Edginton

2025

  1. Chelle P, Hajducek D, Iserman E, Iorio A, Edginton AN, the International Prophylaxis Study Group. Exploring the impact of laboratory reagents on pharmacokinetic profiling. Haemophilia. 2025

2024

  1. Suryavanshi SV, Wang S, Hajducek DM, Hamadeh A, Yeung CHT, Maglalang PD, Ito S, Autmizguine J, Gonzalez D, Edginton AN. Coupling Pre- and Postnatal Infant Exposures with Physiologically Based Pharmacokinetic Modeling to Predict Cumulative Maternal Levetiracetam Exposure During Breastfeeding. Clin Pharmacokinet. 2024 Nov 25. doi: 10.1007/s40262-024-01447-3.Ìý
  2. Najjar A, Hamadeh A, Krause S, Schepky A, Edginton AN. Global sensitivity analysis of Open Systems Pharmacology Suite physiologically based pharmacokinetic models. CPT: Pharmacometrics & Systems Pharmacology. 2024 13(8): 1394-1408. doi: 10.1002/psp4.13256.Ìý
  3. °ä³ó±ð±ô±ô±ðÌý±Ê, Hajducek D, Thibaudeau K, Hobson N, Iorio A, Shapiro A, Edginton AN .ÌýDevelopment of a Plasminogen Population PK model supporting prophylactic replacement therapy for Plasminogen deficient patients within the WAPPS-Hemo platform.ÌýHaemophilia.Ìý2024; 30: 988–997.Ìýdoi: 10.1111/hae.15027
  4. Keyvani F, Poudineh M, Soltani M, Zhao Y, Shakeri A, Chelle P, Rahman F, Mahshid S, Quadrilatero J, Nekkar P, Edginton AN. Integrated Electrochemical Aptamer Biosensing and Colorimetric pH Monitoring via Hydrogel Microneedle Assays for Assessing Antibiotic Treatment. Advanced Science.Ìý 2024 11(41): e23-9027. doi: 10.1002/advs.202309027.Ìý
  5. Kim M-S, Hajducek D, Gilbert J, Iorio A, Jilma B, Edginton AN. Kinetic modeling for BT200 to predict the level of plasma-derived coagulation factor VIII in humans. AAPS Journal. 26, 81 (2024). doi: 10.1208/s12248-024-00952-4
  6. Thompson E, Jeong A, Helfer V, Shakhnovich V, Edginton AN, Balevic S, James L, Collier D, Anand R, Gonzalez D, Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee. Physiologically-based pharmacokinetic modeling of pantoprazole to evaluate the role of CYP2C19 genetic variation and obesity in the pediatric population. CPT: Pharmacometrics & Systems Pharmacology. 2024 13(8): 1394-1408. doi: 10.1002/psp4.13167.
  7. Karatza E, Sinha J, Maglalang PD, Edginton A, Gonzalez D. Physiologically-Based Pharmacokinetic Modeling of Total and Unbound Valproic Acid to Evaluate Dosing in Children With and Without Hypoalbuminemia. Clinical Pharmacokinetics.Ìý2024 63(10):1435-1448.Ìýdoi: 10.1007/s40262-024-01418-8.
  8. Maglalang PD, Sinha J, Zimmerman K, McCann S, Edginton A, Hornik CP, Hornik CD, Muller WJ, Al-Uzri A, Meyer M, Chen JY, Anand R, Perrin EM, Gonzalez D; Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee. Application of Physiologically Based Pharmacokinetic Modeling to Characterize the Effects of Age and Obesity on the Disposition of Levetiracetam in the Pediatric Population. Clinical Pharmacokinetics. 2024 63(6)885-899. doi: 10.1007/s40262-024-01367-2.
  9. Hajducek DM, Chelle P, Iorio A, Iserman E, Edginton AN. Estimated prophylactic dose required to achieve 3% trough as a function of age and concentrate class in multi-country severe WAPPS-Hemo Hemophilia patients. Haemophilia. 2024;30 (4), 925-932. doi: 10.1111/hae.15032
  10. Hirniak S, Edginton AN, Iorio A, Alsabbagh MW, Hajducek DM, Wong WWL. Health utilities in adults with hemophilia A: A retrospective cohort study. Haemophilia. 2024;30(3):733-742. doi: 10.1111/hae.14979
  11. Hunt JP, Dubinsky S, McKnite AM, Cheung KWK, van Groen B D, Giacomini K M, de Wildt SN, Edginton A N, & Watt K M. (2024). Maximum likelihood estimation of renal transporter ontogeny profiles for pediatric PBPK modeling. CPT: pharmacometrics & systems pharmacology, 13(4), 576–588. doi: 10.1002/psp4.13102
  12. Matino D, Germini F, Chan A, Decker K, Iserman E, Chelle P, Edginton A, Oladoyinbo O, Trinari E, Keepanasseril A, Iorio A. Canadian clinical experience on switching from standard half-life recombinant factor VIII (rFVIII), octocog alfa, to extended half-life rFVIII, damoctocog alfa pegol, in persons with hemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada. Haemophilia. 2024;30(2):345-354. doi:10.1111/hae.14960
  13. Yeung CHT, Autmizguine J, Dalvi P, Denoncourt A, Lto S, Katz P, Rahman M, Theoret Y, Edginton AN. Maternal Ezetimibe Concentrations Measured in Breast Milk and its Use in Breastfeeding Infant Exposure Predictions. Clinical Pharmacokinetics. 2024; 63(3):3`7-332. doi: 10.1007/s40262-023-01345-0.
  14. Hunt JP, Dubinsky S, McKnite AM, Cheung KWK, van Groen BD, Giacomini KM, de Wildt SN, Edginton AN, Watt KM. Maximum likelihood estimation of renal transporter ontogeny profiles for pediatric PBPK modeling. CPT Pharmacometrics & Systems Pharmacology. 2024 13(4): 576-588. doi: 10.1002/psp4.13102.  
  15. Hamadeh A, Nash JF, Bialk H, Styczynski P, Troutman J, Edginton A. Mechanistic skin modeling of plasma concentrations of sunscreen active ingredients following facial application. Journal of Pharmaceutical Sciences. 2024 113(3): 806-825. doi: 10.1016/j.xphs.2023.09.017.Ìý

2023

  1. Dubinsky SDJ, Watt KM, Imburgia CE, Mcknite AM, Hunt JP, Rice C, Rower JE, Edginton AN. Anakinra Removal by Continuous Renal Replacement Therapy: An Ex Vivo Analysis. Critical Care Explorations. 2023 Dec 14;5(12):e1010. doi: 10.1097/CCE.0000000000001010.
  2. Yeung CHT, Bertrand KA, Best BM, Capparelli E, Chambers CD, Hajducek DM, Hamadeh A, Ito S, Momper JD, Edginton AN. Cannabidiol Exposure Through Maternal Marijuana Use: Predictions in Breastfed Infants. Clinical Pharmacokinetics. 2023 Nov;62(11):1611-1619. doi: 10.1007/s40262-023-01307-6.
  3. Hamadeh A, Najjar A, Troutman J, Edginton A. Enhancement of Skin Permeability Prediction through PBPK Modeling, Bayesian Inference, and Experiment Design. Pharmaceutics. 2023 Nov 24;15(12):2667. doi: 10.3390/pharmaceutics15122667. PMID: 38140008; PMCID: PMC10747907.
  4. Yeung C, Bertrand K, Best B, Capparelli E, Chambers C, Ito S, Momper J, Edginton A. Cannabidiol exposures in breastfed infants compared to children as predicted by physiologically based pharmacokinetic modeling. Clinical Pharmacology & Therapeutics. 2023;113(S1):S37.doi: 10.1007/s40262-023-01307-6
  5. Yu JK, Wong WWL, Keepanasseril A, Iorio A, Edginton AN. Cost-utility analysis of emicizumab for the treatment of severe hemophilia A patients in Canada.ÌýHaemophilia. 2023;29(2):488-497. doi:10.1111/hae.14723
  6. Cardoso E, Guidi M, Nauwelaerts N, Nordeng H, Teil M, Allegaert K, Smits A, Gandia P, Edginton A, Ito S, Annaert P, Panchaud A. Safety of medicines during breastfeeding - from case report to modeling: a contribution from the ConcePTION project. Expert Opinion on Drug Metabolism & Toxicology. 2023 Jan-Jun;19(5):269-283. doi: 10.1080/17425255.2023.2221847.Ìý
  7. Yeung CHT, Houle SKD, Anderson PO, Best BM, Dubinsky S, Edginton AN. Addressing maternal medication use during breastfeeding using clinical resources and a novel physiologically based pharmacokinetic model-derived metric: A qualitative study.ÌýFrontiers in Pediatrics. 2023;11:1147566. doi:10.3389/fped.2023.1147566
  8. Parmar KR, Lukka PB, Wagh S, Temrikar ZH, Liu J, Lee RE, Braunstein M, Hickey AJ, Robertson GT, Gonzalez-Juarrero M, Edginton A, Meibohm B. Development of a Minimalistic Physiologically Based Pharmacokinetic (mPBPK) Model for the Preclinical Development of Spectinamide Antibiotics. Pharmaceutics. 2023 Jun 17;15(6):1759. doi: 10.3390/pharmaceutics15061759.
  9. Yeung CHT, Beers JL, Jackson KD, Edginton AN. Verifying in vitro-determined enzyme contributions to cannabidiol clearance for exposure predictions in human through physiologically-based pharmacokinetic modeling.ÌýCPT Pharmacometrics & Systems Pharmacology. 2023;12(3):320-332. doi:10.1002/psp4.12908

2022

  1. Gerhart JG, Carreño FO, Edginton AN, Sinha J, Perrin EM, Kumar KR, Rikhi A, Hornik CP, Harris V, Ganguly S, Cohen-Wolkowiez M, Gonzalez D; Best Pharmaceuticals for Children Act—Pediatric Trials Network Steering Committee. Development and Evaluation of a Virtual Population of Children with Obesity for Physiologically Based Pharmacokinetic Modeling. Clinical Pharmacokinetics. 2022 Feb;61(2):307-320. doi: 10.1007/s40262-021-01072-4.Ìý
  2. Yu JK, Wong WWL, Keepanasseril A, Iorio A, Edginton AN.ÌýCost-utility analysis of emicizumab for the treatment of severe hemophilia A patients in Canada.ÌýHaemophilia.Ìý2022;Ìý1-Ìý1 doi: 10.1111/hae.147230.Ìý
  3. Grassman V, Hajducek D, Edginton AN, Bouskill V, Brown C, Carcao M, Lillicrap D, O’Rourke R, Sinha R, Stoffman J, Wakefield C, Rand ML, Blanchette V. A Real-World Population Pharmacokinetic (PK) Study of Two Recombinant Factor VIII (rFVIII) Concentrates in Boys with Severe Hemophilia a without Inhibitors. Blood. 2022;  140 (S1): 8453–8455. doi: 10.1182/blood-2022-160289
  4. Chelle P, Iorio A, Edginton AN. A Personalized Limited Sampling Approach to Better Estimate Terminal Half-life of FVIII concentrates. Journal of Thrombosis and Haemostasis 2022 Jun 26. doi: 10.1111/jth.15803.
  5. Dubinsky, S., Malik, P., Hajducek, D. M., & Edginton, A. Determining the Effects of Chronic Kidney Disease on Organic Anion Transporter1/3 Activity Through Physiologically Based Pharmacokinetic Modeling. Clinical Pharmacokinetics, (2022).  61(7), 997–1012. doi: 10.1007/s40262-022-01121-6
  6. Stitt G, Dubinsky S, Edginton A, et al. Antimicrobial Dosing Recommendations in Pediatric Continuous Renal Replacement Therapy: A Critical Appraisal of Current Evidence.Ìý Frontiers in Pediatrics. 2022;10:889958. doi:10.3389/fped.2022.889958
  7. Gerhart JG, Carreño FO, Loop MS, Lee CR, Edginton AN, Sinha J, Kumar KR, Kirkpatrick CM, Hornik CP, Gonzalez D; Best Pharmaceuticals for Children Act - Pediatric Trials Network Steering Committee. Use of Real-World Data and Physiologically-Based Pharmacokinetic Modeling to Characterize Enoxaparin Disposition in Children With Obesity. Clinical Pharmacology & Therapeutics. 2022 Aug;112(2):391-403. doi: 10.1002/cpt.2618.
  8. Gerhart JG, Carreño FO, Edginton AN, et al. Development and Evaluation of a Virtual Population of Children with Obesity for Physiologically Based Pharmacokinetic Modeling. Clinical Pharmacokinetics. 2022;61(2):307-320. doi:10.1007/s40262-021-01072-4
  9. Gerhart JG, Carreño FO, Ford JL, Edginton AN, Perrin EM, Watt KM, Muller WJ, Atz AM, Al-Uzri A, Delmore P, Gonzalez D; Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee. Use of physiologically-based pharmacokinetic modeling to inform dosing of the opioid analgesics fentanyl and methadone in children with obesity. CPT Pharmacometrics & Systems Pharmacology. 2022 Jun;11(6):778-791. doi: 10.1002/psp4.12793.
  10. Yun YE, Calderon-Nieva D, Hamadeh A, Edginton AN. Development and Evaluation of an In Silico Dermal Absorption Model Relevant for Children. Pharmaceutics. 2022; 14(1):172. Doi: 10.3390/pharmaceutics14010172
  11. Versloot O, Iserman E, Chelle P, et al. Predicting Individual Changes in Terminal Half-Life After Switching to Extended Half-Life Concentrates in Patients with Severe Hemophilia.ÌýHemasphere. 2022;6(4):e694. doi:10.1097/HS9.0000000000000694
  12. Ford J, Gerhart J, Edginton AN, Yanovski J, Hon CYY, Gonzalez D. Physiologically Based Pharmacokinetic Modeling of Metformin in Children and Adolescents with Obesity. The Journal of Clinical Pharmacology. 2022 ;62(8):960-969. doi:10.1002/jcph.2034
  13. Guimarães M, Maharaj A, Edginton A, Vertzoni M, Fotaki N. Understanding the Impact of Age-Related Changes in Pediatric GI Solubility by Multivariate Data Analysis. Pharmaceutics. 2022; 14(2):356. doi: 10.3390/pharmaceutics14020356
  14. Malik PRV, Hamadeh A, Edginton AN. Model-Based Assessment of the Contribution of Monocytes and Macrophages to the Pharmacokinetics of Monoclonal Antibodies. Pharmaceutical Research. 2022. 39(2): 239-250.Ìýdoi: 10.1007/s11095-022-03177-2.
  15. Gerhart JG, Balevic S, Sinha J, Perrin EM, Wang J, Edginton AN, Gonzalez D. Characterizing Pharmacokinetics in Children With Obesity-Physiological, Drug, Patient, and Methodological Considerations. Frontiers in Pharmacology.2022;13:818726. doi: 10.3389/fphar.2022.818726.
  16. Gerhart JG, Carreño FO, Ford JL, et al. Use of physiologically-based pharmacokinetic modeling to inform dosing of the opioid analgesics fentanyl and methadone in children with obesity.ÌýCPT Pharmacometrics & Systems Pharmacology. 2022;11(6):778-791. doi:10.1002/psp4.12793
  17. Hamadeh, A, Troutman, J, Najjar, A, Edginton, AN. A Mechanistic Bayesian Inferential Workflow for Estimation of In Vivo Skin Permeation From In Vitro Measurements. Journal of Pharmaceutical Sciences. 2022; 11(3): 838-851.
  18. Dubinsky S, Watt K, Saleeb S, Ahmed B, Carter C, Yeung CHT, Edginton A.Pharmacokinetics of Commonly Used Medications in Children Receiving Continuous Renal Replacement Therapy: A Systematic Review of Current Literature. Clinical Pharmacokinetics. 61(2): 189-229. doi: 10.1007/s40262-021-01085-z.